“RUKOBIA, in conjunction with the other antiretrovirals I’m taking, got me to undetectable. And I’ve stayed there.”

Dennis, taking RUKOBIA as part of an HIV-1 regimen.
Compensated by ViiV Healthcare.

Results with RUKOBIA

In combination with other HIV-1 medications, starting RUKOBIA may get you undetectable

RUKOBIA works differently from other HIV-1 treatments by stopping the virus from attaching to your CD4+ T-cells.

RUKOBIA has proven through ~5 years (240 weeks) to help decrease viral load even in people who were previously unable to construct an effective regimen.*

Adults taking RUKOBIA have had a robust improvement in their CD4+ T-cell count through ~5 years.*

RUKOBIA is not for use alone. RUKOBIA should be taken along with an HIV-1 treatment regimen recommended by your doctor.

LIVING WITH HIV AND
INTERESTED IN SHARING
YOUR STORY?

If you are 18 years or older,
please call 1-888-203-8565
to find out more about this opportunity

*Based on data from the BRIGHTE trial, where 371 adults received RUKOBIA plus their existing regimen. All participants who entered the study met the following criteria: virus was detectable while on their current regimen (viral load ≥400 and copies/mL), and virus was resistant to many HIV-1 treatments. All participants had limited treatment options left.

LIVING WITH MDR HIV AND INTERESTED IN SHARING YOUR STORY?

If you are 18 years or older, 

please call 1-888-203-8565 to find out more about this opportunity. 

RUKOBIA could make the difference

RUKOBIA may help reduce the HIV viral load for people with no or limited options left.

In a clinical study of 371 adults with HIV‍-‍1, RUKOBIA was added to a treatment regimen and was evaluated at Day 8, Weeks 24, 96, and 240.

People who entered the study met the following criteria:

  • The virus was detectable while on their current regimen (viral load greater than or equal to 400 copies/mL)
  • The virus was resistant to many HIV‍‍-‍1 treatments
  • They had limited treatment options (no more than 2 antiretroviral classes remaining)

The study inlcuded people with advanced HIV‍‍-‍1:

  • 89% had viral load greater than 1000 copies/mL
  • 75% had CD4+ T-cells* less than 200 cells/mm3
  • 86% had history of AIDS
  • 30% had CD4+ T-cells less than 20 cells/mm3

*CD4+ T-cells (also called T-cells) are white blood cells that help fight infections. CD4+ T-cell count is the number of CD4+ T-cells per mm3 of blood.

AIDS=acquired immune deficiency syndrome.

A ~5 year clinical study showed that

A ~5 year clinical study showed that

RUKOBIA may help you reach and stay undetectable

Viral load decrease*:

viral load decrease chart

At Day 9, all participants still on their current regimen were changed to RUKOBIA along with a tailored treatment† regimen that best fit the needs of each person for the remainder of the study.

Results may vary.

*Calculated from viral load changes: -0.79 log10 (RUKOBIA + current regimen) and -0.17 log10 (sugar pill + current regimen).

†The tailored treatment regimen was based on the needs of each person and the number of active antiretroviral therapies remaining to replace their current regimen, which had stopped working.

Some people reached undetectable and remained undetectable through ~5 years* 

More than half of the 272 people who took RUKOBIA along with a tailored treatment regimen1 reached undetectable by 24 weeks and 45% remained undetectable at 240 weeks

  • Undetectable means reducing the HIV in your blood to very low levels
  • In the study, undetectable was defined as less than 40 copies/mL

*Results my vary

Average CD4+ T-cell count increased over time.

Some participants had improved CD4+ T-cell counts on RUKOBIA

As part of a tailored treatment regimen, RUKOBIA increased and maintained
the number of infection-fighting CD4+ T‍-‍cells in the immune system

AVERAGE INCREASE IN CD4+ T-CELL COUNTS FROM DAY 0

CD4 cell count

For those participants who started the clinical study with very low CD4+ T-cell count (below 20 cells/mm3), RUKOBIA, added to a tailored treatment regimen, helped increase their CD4+ T-cells by more than 200 cells/mm3 on average through 240 weeks

Learn more about taking RUKOBIA

READ MORE

FSTWCNT230003